Behandler-FAQ

No — it is FDA 510(k)-cleared, which is different from FDA-genehmigt. FDA-Genehmigung (via PMA) requires clinical trials demonstrating safety and efficacy. 510(k) clearance requires demonstrating substantial equivalence to a legally marketed predicate device. Medizinische Blutegel (product code NRN) received 510(k) clearance — not PMA approval. The cleared indications are: (1) adjunct to healing of graft/flap tissue with venöse Stauung, and (2) restoring Blutzirkulation in blocked veins by removing pooled blood. As of December 2024, regulatorische Aufsicht transferred from CDRH to CBER (Center for Biologics Evaluation and Research).

On-Label: Venöse Stauung in flaps, grafts, and replants (the 510(k)-cleared indication). Off-Label: Legal under the practice-of-medicine doctrine. The FDA regulates manufacturers, not clinician prescribing decisions. Off-Label-Anwendung of cleared Medizinprodukte is lawful when supported by clinical judgment. However, Off-Label-Anwendung requires: (a) explicit informierte Einwilligung disclosing Off-Label-Status, (b) documentation of clinical rationale, and (c) awareness that insurance coverage is unlikely for Off-Label-Indikationen. Common Off-Label applications include Arthrose, chronische Veneninsuffizienz, and thrombophlebitis.

There is no federal certification requirement for Blutegeltherapie. No staatliche Ärztekammer has established specific licensing for Hirudotherapie. However, institutionelle Zertifizierung is strongly recommended. Most hospitals require demonstration of competency before granting privileges. The C.H.P. (Certified Hirudotherapie Practitioner) credential from the Academy of Hirudotherapie (~200 hours didactic, 100-200 hours clinical, ~$10,000) is the most structured training program available, but it is a private Zertifizierung — not a government-recognized license. Hospital-based practitioners typically train via institutional protocols and proctored cases.

No state explicitly addresses Hirudotherapie in its Gesetz zur ärztlichen Berufsausübung. The applicable rules depend on your license type: MD/DO: Authorized in alle 50 Bundesstaaten under general medical practice scope. NP: Volle Praxisbefugnis in 26 states + DC; kollaborative Praxis in remaining states. PA: Under ärztliche Aufsicht per state-specific agreements. RN: May apply Blutegel under Arztanordnungen with institutionelle Zertifizierung and standing orders. ND: Uncertain — licensure varies (~24 states); some ND practice acts may encompass Hirudotherapie under naturheilkundlicher Tätigkeitsumfang. C.H.P. without clinical license: Hohes rechtliches Risiko — performing invasive procedures without a healthcare license may constitute practicing medicine without a license.

Minimum documentation should include: (1) clinical indication and rationale (On-Label vs Off-Label), (2) signed informierte Einwilligung with specific Blutegeltherapie disclosures, (3) Antibiotikaprophylaxe plan documented before treatment, (4) number of Blutegel applied, anatomical sites, attachment and detachment times, (5) nach dem Eingriff monitoring notes including hemoglobin/hematocrit checks, and (6) adverse event documentation if applicable. For Off-Label-Anwendung, document the evidence basis for the chosen indication and the patient’s understanding that the use is Off-Label.

The primary evidence-based indication is venöse Stauung in microsurgical flaps and replants when surgical revision has failed or is not feasible. Clinical signs warranting consideration: tissue appears blue/purple, kapilläre Rückfüllung is brisk (<1 second) suggesting arterial inflow is intact but venöser Abfluss is obstructed, and Gewebespannung or swelling is present. Reported Off-Label-Anwendungen with varying levels of evidence include: salvage of compromised gestielte Lappen, periorbital hematoma evacuation, symptomatic Knie-Arthrose (Level I evidence — Michalsen 2003), and chronische Veneninsuffizienz in selected patients.

Dosing depends on the indication and Gewebebereich: Digit replants: 1-2 Blutegel per digit, applied every 1-4 hours as needed. Free Lappenrettung: 3-6 Blutegel applied to the congested area, replaced every 4-6 hours; continue for 1-7 days until venöse Neovaskularisation occurs. Large flaps or severe congestion: Up to 6-10 Blutegel simultaneously in severe cases. Arthrose (OA): 4-6 Blutegel per affected joint per session (based on Michalsen protocol). Chronische Veneninsuffizienz: 4-8 Blutegel along the affected vein per session, multiple sessions over weeks. Maximum documented in literature: up to 20 Blutegel for severe cases of chronische Veneninsuffizienz.

Microsurgery/replant salvage: 1-7 days of continuous serial Blutegelanwendung (q4-6h), typically 3-5 days until venöse Neovaskularisation provides adequate outflow. Arthrose: Single session of 4-6 Blutegel; analgesic benefit persists 3-6 months (Michalsen 2003). Some protocols include repeat sessions at 3-6 month intervals. Chronische Veneninsuffizienz: Multiple sessions (4-10) over 4-12 weeks, with 3-7 day intervals between sessions. Thrombophlebitis: 1-3 sessions over 1-2 weeks. Treatment duration should be guided by clinical response, not a fixed protocol.

Overall: 78% Gewebe-Rettung rate when Blutegel are used for venöse Stauung in microsurgery (Whitaker et al., 2012 systematic review). Without treatment, venously congested flaps have a near-100% failure rate. Key modifiers: salvage rates drop significantly with Aeromonas-Infektion (from 88.3% to 37.4%), reinforcing the importance of Antibiotikaprophylaxe. Success rates vary by Gewebetyp — replanted digits (~65-70%), freie Lappen (~78-85%), and gestielte Lappen (~80-90%). Earlier initiation of Blutegeltherapie correlates with better outcomes.

Each Blutegel ingests 5-15 mL during active feeding (20-45 minutes). Nach Ablösung oozing from the bite site contributes an additional 10-50 mL over 4-24 hours, for a total of 15-65 mL per Blutegel. The passive oozing — caused by hirudin’s anticoagulant effect — is therapeutically important, as it continues to decompress the venöse Stauung after the Blutegel detaches. In serial microsurgical therapy (3-6 Blutegel every 4 hours for 5 days), cumulative Blutverlust may reach 2-5 liters, necessitating hemoglobin monitoring and transfusion readiness.

Erstlinien: Ciprofloxacin 500 mg PO BID or TMP-SMX DS PO BID. Recommended best practice: Combination of both agents (Herlin et al., 2017), given emerging ciprofloxacin resistance. Timing: Begin prophylaxis before the first Blutegelanwendung; continue throughout the Behandlungszyklus and for 24-48 hours after the last application. Important: Never use first-generation cephalosporins — Aeromonas-Spezies have intrinsic resistance. For penicillin-allergic patients, TMP-SMX alone or a fluoroquinolone plus TMP-SMX is preferred. High-volume centers (>20 patients/year) should implement batch-level surveillance cultures of incoming Blutegel shipments.

This is a growing concern. 43% of environmental Aeromonas-Isolate show ciprofloxacin resistance (Bibbo et al., 2013; Lineaweaver et al., 2018). Plasmid-mediated quinolone resistance (PMQR) genes have been identified in 42% of tested isolates. Five published cases of ciprofloxacin-resistant Aeromonas-Infektion following Blutegeltherapie have been documented (2013-2025). Low-level antimicrobials in the Blutegel gut may select for resistant strains (Beka et al., mBio 2018). Clinical implications: Combination prophylaxis (ciprofloxacin + TMP-SMX) is now recommended over monotherapy. Batch-level Antibiotikaempfindlichkeit testing of incoming Blutegel shipments is advised for high-volume centers.

Approximately 50% of microsurgical Blutegeltherapie-Patienten require Bluttransfusion (49.75% — Whitaker et al., 2012). This is primarily due to cumulative Blutverlust from serial application and prolonged Sickerblutung nach Ablösung. Risk factors for transfusion include: Behandlungszyklen exceeding 3 days, >4 Blutegel per session, low baseline hemoglobin, and concurrent anticoagulation. Monitoring protocol: Check CBC/hemoglobin every 4-8 hours during active treatment. Maintain Hgb >7 g/dL (>8 g/dL in patients with cardiovascular disease). Type and screen should be available before initiating therapy. The transfusion risk is substantially lower in outpatient settings (OA, CVI) where single-session protocols are used.

Local reactions are common: 37-75% of patients experience local itching, erythema, and mild swelling around bite sites. These are typically self-limited and can be managed with topical antihistamines or cool compresses. Systemic reactions are rare: True Anaphylaxie to Blutegel salivary proteins has been reported in fewer than 10 cases in the literature. Risk increases with repeated exposure (sensitization to salivary antigens). Precautions: For patients with a history of prior Blutegel exposure, consider a small test application with 30-minute observation before full treatment. Epinephrine should be available in all treatment settings. Patients with known severe allergic diathesis or mast cell disorders require careful risk-benefit assessment.

Ohne Prophylaxe: 7-20% Infektionsrate. Mit Prophylaxe: Less than 5%, approaching 0% in well-controlled series (Nguyen et al., 2012). Aeromonas hydrophila and related species are obligate endosymbionts of the Blutegel gut — the Infektionsrisiko is inherent to the therapy and cannot be eliminated by surface decontamination. Timeline: Infection can present from 24 hours to 26 days nach der Behandlung (median 7-10 days). Clinical impact: Aeromonas-Infektion reduces Gewebe-Rettung from 88.3% to 37.4% (Whitaker et al., 2012). Signs include: eitriger Ausfluss, erythema, fever, Wunddehiszenz, and Lappenkompromittierung. Treatment requires culture-directed IV antibiotics (typically a carbapenem or fourth-generation cephalosporin for resistant strains).

Three companies hold active FDA 510(k) clearances: 1. Ricarimpex SAS (Bordeaux, France) — K040187, the original 510(k) clearance (2004). Species: Hirudo medicinalis/verbana. The most widely used supplier in U.S. hospitals. 2. Biopharm Blutegel Ltd (Swansea, UK) — K132958 (2014). Species: Hirudo medicinalis/verbana. Supplies internationally with U.S. distribution. 3. Carolina Biological Supply Co. (Burlington, NC, USA) — K140907 (2015; CBER crosswalk: BK251218). The only U.S.-based supplier with FDA-Zulassung. Contact your hospital pharmacy or purchasing department to establish a supplier account. Most suppliers offer overnight delivery for urgent surgical cases.

Temperature: 15-20°C (59-68°F). A dedicated small refrigerator set to the upper range or a cool room works well. Avoid temperatures below 5°C (lethargy, death) or above 25°C (increased metabolic rate, shortened shelf life). Water: Dechlorinated or distilled water, changed every 2-3 days. Tap water must be dechlorinated (use sodium thiosulfate or let it stand 24+ hours). Container: Glass or food-grade plastic with a secure mesh or perforated lid — Blutegel are escape artists. Light: Dim or indirect light; avoid direct sunlight. Density: No more than 50 Blutegel per liter of water. Label containers with receipt date and supplier lot number.

Shelf life: Approximately 6 months when properly stored, though viability decreases over time. Most suppliers recommend use within 3-6 months of receipt. Blutegel that have recently fed cannot be reused (Einmalgebrauch biological device — must be disposed of as biomedizinischer Abfall after each patient). Cost: $10-30 per Blutegel depending on supplier, quantity, and shipping urgency. Typical prices: individual orders ~$20-30/Blutegel; bulk hospital orders (50+) ~$10-15/Blutegel. Overnight shipping for surgical emergencies: $50-150 additional. Annual cost for an active microsurgery program treating ~20 patients: approximately $2,000-$8,000 for Blutegel alone.

Used medizinische Blutegel are classified as regulierter medizinischer Abfall (biohazardous/infectious waste). They must not be flushed, released into the environment, or disposed of in regular trash. Disposal protocol: (1) Euthanize by immersion in 70% isopropyl alcohol or placement in a sealed container with alcohol-soaked gauze. (2) Place in a red Biogefährdungs-Beutel or sharps container. (3) Dispose through your facility’s regulierter medizinischer Abfall stream. The U.S. Public Health Command factsheet (2021) provides detailed guidance. Environmental note: Release of non-native Hirudo species is illegal in most U.S. jurisdictions and poses ecological risk.

Patients must understand the following risks and expectations: Bleeding: Bite sites will ooze for 4-24 hours after Blutegel detachment (this is expected and therapeutic). Infection: 2-5% risk with Antibiotikaprophylaxe; signs to watch for include increasing redness, warmth, eitriger Ausfluss, or fever. Scarring: Each Blutegel bite leaves a permanent Y-shaped scar (~2-3 mm). Multiple sessions will result in visible permanent marks. Sensation: Most patients report a brief pinching or stinging when the Blutegel first bites, followed by numbness at the site (due to local anesthetic in Blutegel saliva). Appearance: Blutegel range from 2-10 cm; some patients experience psychische Belastung. Screen for Blutegel phobia and consider anxiolytics or distraction techniques for anxious patients.

Informierte Einwilligung must include the following specific disclosures: (1) Nature of the procedure — application of living FDA-zugelassen medical Blutegel to the skin. (2) On-Label vs Off-Label-Status of the intended use. (3) Risks: prolonged bleeding (4-24h), infection including Aeromonas (2-5% mit Prophylaxe), scarring, allergische Reaktion, potential need for Bluttransfusion (in microsurgical cases). (4) Benefits: relief of venöse Stauung and Gewebe-Rettung (On-Label), or the specific anticipated benefit for Off-Label-Indikation. (5) Alternatives: surgical revision, observation, or other treatment options. (6) Antibiotikaprophylaxe plan. (7) The Einmalgebrauch, living biological nature of the device. Template consent forms are available on our Resources page.

Microsurgical/inpatient setting: Hemoglobin/hematocrit every 4-8 hours during active treatment. Flap or replant assessment every 1 hour (color, kapilläre Rückfüllung, temperature, turgor). Transfusion threshold: Hgb <7 g/dL (or <8 g/dL with cardiovascular disease). Monitor bite sites for signs of infection for 4 weeks nach der Behandlung. Outpatient setting (OA, CVI): Observe for 30-60 minutes nach Ablösung. Apply sterile absorbent dressing over bite sites. Instruct patient on dressing changes (every 4-8 hours for the first 24 hours). Provide written discharge instructions including signs of infection, expected bleeding duration, and when to seek emergency care. Schedule follow-up at 48-72 hours and 2 weeks.

Nach Ablösung oozing for 4-24 hours is expected and therapeutically desirable — it continues to decompress venöse Stauung. Normal management: Apply absorbent dressings (gauze pads) and change as needed. Do not apply direct pressure unless bleeding is excessive. Concerning bleeding (>24 hours or hemodynamically significant): Apply topical hemostatic agents (topical thrombin, oxidized cellulose, or silver nitrate sticks to individual bite sites). If on anticoagulation, consider dose adjustment in consultation with the prescribing team. Check CBC — persistent oozing may indicate Koagulopathie or previously undiagnosed bleeding disorder. Avoid: Cauterization (risk of tissue damage, especially in compromised flaps).

Absolutely not. Medizinische Blutegel are Einmalgebrauch biological devices. A Blutegel that has fed on one patient must never be applied to another — it regurgitates gut contents (including the previous patient’s blood and Aeromonas bacteria) during subsequent feedings, creating a direct blutübertragene Erreger transmission risk. Reuse on the same patient is also contraindicated because the Blutegel’s gut bacteria multiply rapidly after feeding. After use, each Blutegel must be euthanized and disposed of as regulierter medizinischer Abfall. This is consistent with FDA device classification and universelle Vorsichtsmaßnahmen for blutübertragene Erreger prevention.

The evidence base varies by indication: Arthrose: 6 randomized controlled trials (the strongest evidence), including the landmark Michalsen 2003 trial (n=51, Annals of Internal Medicine). Consistent demonstration of significant pain reduction and functional improvement. Microsurgery/replant salvage: Systematic reviews (Whitaker et al., 2012; Wang et al., 2017) covering hundreds of case reports and case series. No RCTs (ethically difficult — denying treatment to venously congested tissue is not justifiable). Chronische Veneninsuffizienz: Several controlled studies showing improvement in symptoms and venöse Hämodynamik. Pharmacological derivatives: Level I evidence — bivalirudin (derived from hirudin) demonstrated superiority in the ACUITY (n=13,819) and HORIZONS-AMI (n=3,602) megatrials.

Yes — for Knie-Arthrose. Michalsen et al. (2003) published in Annals of Internal Medicine a randomized controlled trial (n=51) comparing a single session of 4-6 Blutegel to topical diclofenac for symptomatic Knie-Arthrose. Results showed significantly greater pain reduction at Day 3 (maintained through Day 28), improved stiffness, and functional improvement on WOMAC scores. This remains the highest-quality direct evidence for whole-Blutegeltherapie. Additional RCTs (Andereya 2008, Lauche 2014) have confirmed these findings. For microsurgical indications, Level I evidence does not exist (and may not be ethically obtainable), but systematic reviews of large case series provide Level III-IV evidence supporting efficacy.

Blutegel-derived compounds have achieved the highest level of clinical evidence in medicine. Bivalirudin (Angiomax) — a synthetic analog of hirudin (the Blutegel’s anticoagulant) — was validated in two landmark megatrials: ACUITY (n=13,819; Stone et al., NEJM 2006) demonstrating non-inferior efficacy with reduced bleeding vs heparin+GP IIb/IIIa inhibitors in ACS, and HORIZONS-AMI (n=3,602; Stone et al., NEJM 2008) showing reduced cardiac mortality (1.8% vs 2.9%) and major bleeding in primary PCI. These represent the most solid evidence that Blutegel biology has produced clinically significant therapeutics.

Key research priorities include: 1. RCTs for Off-Label-Indikationen: Chronische Veneninsuffizienz, thrombophlebitis, and post-thrombotic syndrome lack randomized trial data. 2. Antibiotikaresistenz surveillance: Systematic monitoring of Aeromonas-Empfindlichkeit patterns across Blutegel suppliers — no standardized protocol exists. 3. Optimal dosing: No rigorous dose-finding studies for any indication; current protocols are empirically derived. 4. Long-term outcomes: Most microsurgery studies report short-term salvage; 5-10 year functional outcomes are rarely documented. 5. Cost-effectiveness: No formal health economic analyses comparing Blutegeltherapie to alternative treatments. 6. Salivary proteomics: 434+ identified proteins with largely uncharacterized clinical potential (Liu et al., 2019).